潰瘍性大腸炎:關鍵意見領袖 (KOL) 的考察 - 最新趨勢簡報 (2016年2月)
Ulcerative Colitis: Update Bulletin [Feb 2016]
|潰瘍性大腸炎:關鍵意見領袖 (KOL) 的考察 - 最新趨勢簡報 (2016年2月) Ulcerative Colitis: Update Bulletin [Feb 2016]|
|出版日期: 2016年02月01日||內容資訊: 英文||
本最新趨勢簡報，調查與潰瘍性大腸炎的治療藥相關最新的事件和關鍵意見領袖 (KOL) 對其見解的彙整。
Gain new KOL insights on the latest events happening in Ulcerative Colitis. Topics covered include opinions regarding Phase III data on Johnson & Johnson's Stelara (ustekinumab) in Crohn's disease and the launch of a new study looking at use of the therapy in patients with UC; the recent filing in the US and EU for Amgen's ABP 501 (a proposed adalimumab biosimilar); the FDA advisory committee's decision to recommend approval of Celltrion's CT-P13 (a proposed infliximab biosimilar); as well as opinions on the early development of both Qu Biologics' QBECO and Protagonist Therapeutics' PTG 100.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.